|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.50/-0.54
|
企業價值
14.25M
|
資產負債 |
每股賬面淨值
0.39
|
現金流量 |
現金流量率
--
|
損益表 |
收益
0
|
每股收益
0.69
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consistsof nafamostat product candidates and pre-filled syringe product candidates. |